Inovio Pharmaceuticals Inc
INO2.255USD
-0.035-1.53%
Handelsschluss 11/06, 16:00（ET）Kurse um 15 Minuten verzögert
82.80MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Inovio Pharmaceuticals Inc Unternehmen
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Inovio Pharmaceuticals Inc Informationen
BörsenkürzelINO
Name des UnternehmensInovio Pharmaceuticals Inc
IPO-datumDec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
Anzahl der mitarbeiter134
WertpapierartOrdinary Share
GeschäftsjahresendeDec 08
Addresse660 W. Germantown Pike
StadtPLYMOUTH MEETING
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl19462
Telefon18584103134
Websitehttps://www.inovio.com/
BörsenkürzelINO
IPO-datumDec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
Führungskräfte von Inovio Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+32.11%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+33.04%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Umsatzaufteilung
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 23
Aktualisiert: Sat, Aug 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
3.78%
Deep Track Capital LP
3.73%
BofA Global Research (US)
2.39%
BlackRock Institutional Trust Company, N.A.
0.98%
Geode Capital Management, L.L.C.
0.82%
Andere
88.30%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
3.78%
Deep Track Capital LP
3.73%
BofA Global Research (US)
2.39%
BlackRock Institutional Trust Company, N.A.
0.98%
Geode Capital Management, L.L.C.
0.82%
Andere
88.30%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
6.74%
Investment Advisor
6.45%
Research Firm
3.31%
Investment Advisor/Hedge Fund
2.19%
Individual Investor
0.54%
Bank and Trust
0.26%
Venture Capital
0.04%
Andere
80.47%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
280
10.09M
18.99%
-5.77M
2025Q2
303
13.60M
26.69%
-1.85M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
2023Q2
462
6.56M
29.43%
-5.01M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
2.01M
3.78%
-19.82K
-0.98%
Jun 30, 2025
Deep Track Capital LP
1.98M
3.73%
-1.14M
-36.48%
Jun 30, 2025
BofA Global Research (US)
1.27M
2.39%
-34.38K
-2.63%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
519.03K
0.98%
-1.63M
-75.88%
Jun 30, 2025
Geode Capital Management, L.L.C.
437.55K
0.82%
-409.25K
-48.33%
Jun 30, 2025
Millennium Management LLC
346.87K
0.65%
+346.87K
--
Jun 30, 2025
Renaissance Technologies LLC
328.13K
0.62%
+282.30K
+616.00%
Jun 30, 2025
Northern Trust Investments, Inc.
254.38K
0.48%
-207.32K
-44.90%
Jun 30, 2025
Morgan Stanley & Co. LLC
248.95K
0.47%
+140.66K
+129.90%
Jun 30, 2025
Cubist Systematic Strategies, LLC
171.56K
0.32%
+171.56K
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 12 hours ago
Aktualisiert: 12 hours ago
Name
Anteil
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.02%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
DFA Dimensional US Core Equity Market ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Datum
Art
Verhältnis
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
